NICE
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
Professor Graham Cookson responds to President Donald Trump’s Executive Order on drug prices published earlier this week.
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
OHE celebrates NICE’s 25th anniversary through a series of insights explaining NICE’s first steps and discussing NICE’s present and future role.
NICE at 25: HTA Methods Guidelines – Evolution, not revolution
1 May 2024
OHE celebrates NICE’s 25 anniversary through a series of insights explaining NICE’s first steps and discussing NICE’s present and future role.
How Have HTA Agencies Evolved Their Methods Over Time?
29 April 2024
The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.
The Future of NICE in a Changing HTA Landscape
11 March 2024
To commemorate NICE’s 25th anniversary, this OHE webinar explored the biggest challenges and opportunities for the NICE HTA program over the next 5-10 years.
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
In this insight, commissioned and funded by Chiesi S.p.A, we reflect on the discussions that took place at ISPOR Europe 2023 and how environmental impact is factored into HTA.
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.